Accendra Health ACH
NYSE ACH
$0.21 0.00 (-0.43%)
As of: Oct 23, 2026 · 3:59 PM EDT

Accendra Health (ACH) Other Non Operating Income (2009 - 2021)

Updated

Accendra Health (ACH) recorded Other Non Operating Income of -$1.1 million in FY2024, compared with $3.52 million in FY2023.

Analysis

Accendra Health (ACH) Other Non Operating Income (2009 - 2021) Analysis & Trends

Starting with FY2009, Accendra Health's Other Non Operating Income history includes 8 years.

  • The FY2024 figure is the lowest annual Other Non Operating Income since FY2021.
  • Per Business Quant data, ACH's Other Non Operating Income was $3.52 million in FY2023, -$40.43 million in FY2021 and -$11.22 million in FY2020.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 HCA Healthcare 103.18 Bn 99.19 Bn -
2 Natera 57.81 Bn 53.49 Bn 485.19 Mn
3 Labcorp Holdings 26.94 Bn 24.69 Bn 1.11 Bn
4 Quest Diagnostics 26.85 Bn 24.98 Bn 1.03 Bn
5 Guardant Health 22.51 Bn 18.57 Bn 219.03 Mn
6 Tenet Healthcare 22.37 Bn 11.37 Bn -
7 Fresenius Medical Care AG 13.20 Bn 5.15 Bn 1.52 Bn
8 BrightSpring Health Services 12.39 Bn 10.72 Bn 492.75 Mn
9 Encompass Health 12.26 Bn 11.92 Bn -
10 Accendra Health 16.05 Mn -643.30 Mn 263.41 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2021 -40.43 Mn
Dec 31, 2020 -8.64 Mn
Sep 30, 2020 -308,000.00
Jun 30, 2020 1.86 Mn
Mar 31, 2020 -4.13 Mn
Sep 30, 2014 -14.89 Mn
Jun 30, 2011 -457,000.00
Mar 31, 2011 620,000.00
Dec 31, 2010 1.18 Mn
Sep 30, 2010 392,000.00
Jun 30, 2010 669,000.00
Mar 31, 2010 652,000.00
Dec 31, 2009 1.29 Mn
Sep 30, 2009 1.23 Mn
Jun 30, 2009 1.27 Mn
API Access

Accendra Health Other Non Operating Income API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-non-operating-income&ticker=ACH&period=max&api_key=YOUR_API_KEY